Latest Breaking News On - Bioxcel therapeutics daily - Page 6 : comparemela.com

BioXcel Therapeutics, Inc (NASDAQ:BTAI) Sees Significant Drop in Short Interest

BioXcel Therapeutics, Inc (NASDAQ:BTAI) Sees Significant Drop in Short Interest
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United statesVimal mehtaZurcher kantonalbank zurich cantonalbankBioxcel therapeutics company profileCharles schwab investment management incBioxcel therapeutics incSecurities exchange commissionPricet rowe associates incCanaccord genuity groupJpmorgan chase coGroup plcBioxcel therapeuticsGet free reportExchange commissionSchwab investment managementGeneral group plc

Canaccord Genuity Group Lowers BioXcel Therapeutics (NASDAQ:BTAI) Price Target to $20 00

Canaccord Genuity Group Lowers BioXcel Therapeutics (NASDAQ:BTAI) Price Target to $20 00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesVimal mehtaZurcher kantonalbank zurich cantonalbankJpmorgan chase coGroup plcPricet rowe associates incBioxcel therapeutics incCharles schwab investment management incBioxcel therapeutics company profileCanaccord genuity groupBioxcel therapeuticsGet free reportGenuity groupXcel therapeutics trading downXcel therapeuticsSchwab investment management

BioXcel Therapeutics, Inc (NASDAQ:BTAI) Short Interest Up 69 0% in July

BioXcel Therapeutics, Inc (NASDAQ:BTAI) Short Interest Up 69 0% in July
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesVimal mehtaJavier rodriguezBioxcel therapeutics company profileBioxcel therapeutics incRaymond james associatesMetlife investment managementYork mellon corpSwiss national bankJpmorgan chase coSecurities exchange commissionBioxcel therapeuticsGet free reportXcel therapeutics stock downXcel therapeuticsExchange commission

BioXcel Therapeutics, Inc (NASDAQ:BTAI) Receives $37 86 Consensus Target Price from Analysts

Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) have received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year […]

United statesNew zealand generalNew zealandJavier rodriguezRichardi steinhartSecurities exchange commissionBioxcel therapeutics incBlackrock incWellington management groupBioxcel therapeutics company profileVanguard group incBioxcel therapeuticsGet free reportMarketbeat ratingsXcel therapeutics stock downXcel therapeutics

BioXcel Therapeutics, Inc (NASDAQ:BTAI) Short Interest Up 12 3% in June

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 5,130,000 shares, an increase of 12.3% from the June 15th total of 4,570,000 shares. Based on an average daily volume of 2,290,000 shares, […]

United statesZurcher kantonalbank zurich cantonalbankVimal mehtaRichardi steinhartJpmorgan chase coGroup plcBioxcel therapeutics incBioxcel therapeutics company profilePricet rowe associates incCharles schwab investment management incBioxcel therapeuticsGet free reportXcel therapeutics stock downXcel therapeuticsSchwab investment managementGeneral group plc